SCD and Parkinson disease: Similarly, studies conducted on yeast cells overexpressing human α-Syn, and replicated in both rodents and human primary cells associated altered levels of monounsaturated fatty acids (MUFAs) with α-Syn-related dysfunctions and identified Stetoryl-CoA desaturase (SCD) as a possible therapeutic target for PD [186]; accordingly, SCD inhibitors rescued α-Syn pathology in vitro [187] and in vivo [188,189], preventing α-Syn phosphorylation and reestablishing the physiologic binding of this isoform to lipid membranes.